Evidence map›Paper›PMID 40646080›Full record

ArticleScientific reports2025

Establishment and rescue of fibroblast cell lines carrying a nonsense mutation of RB1 by CRISPR-based base editing.

Youngri Jung, Eunhee Seo, Soyeon Yang, Sangsu Bae, Jeong Hun Kim, Hyeon-Ki Jang, Dong Hyun Jo

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Youngri JungDepartment of Chemistry and Research Institute for Convergence of Basic Sciences, Hanyang University, Seoul, 04763, South Korea.
Eunhee SeoDivision of Chemical Engineering and Bioengineering, College of Art Culture and Engineering, Kangwon National University, Chuncheon-Si, 24341, South Korea.
Soyeon YangDivision of Chemical Engineering and Bioengineering, College of Art Culture and Engineering, Kangwon National University, Chuncheon-Si, 24341, South Korea.
Sangsu BaeDepartment of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, South Korea.
Jeong Hun KimDepartment of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, South Korea.
Hyeon-Ki JangDivision of Chemical Engineering and Bioengineering, College of Art Culture and Engineering, Kangwon National University, Chuncheon-Si, 24341, South Korea. hyeonkijang@kangwon.ac.kr.
Dong Hyun JoDepartment of Anatomy and Cell Biology, Seoul National University College of Medicine, Seoul, 03080, South Korea. lawrenc2@snu.ac.kr.

Funding

Ministry of Education RS-2023-00301850Ministry of Health & Welfare RS-2024-00438476Ministry of Science and ICT, South Korea GTL24021-000Ministry of Science and ICT, South Korea RS-2023-00260351Ministry of Science and ICT, South Korea RS-2024-00400829Seoul National University Hospital 18-2023-0010
6 · The paper itself

Abstract

Pathogenic variants of the RB1 gene have commonly been found in many cancer types, including retinoblastoma. Nonsense mutations are the most common mutation type in retinoblastoma; however, few cell lines mimic nonsense mutations in the RB1 gene that are commonly observed in patients. Here, we established retinoblastoma-like cell lines carrying mono- and bi-allelic nonsense mutations in the RB1 gene. We introduced the R552X mutation using target activation-induced cytidine deaminase base editing and successfully constructed cell lines carrying mono- and bi-allelic mutations. The model cell lines showed decreased RB1 expression at both the mRNA and protein levels, and increased cell proliferation. Furthermore, we rescued the nonsense mutation in the RB1 gene in model cell lines by converting stop codon 552 to tryptophan using an adenine base editor. This approach may be applicable for establishing cell lines with pathogenic variants found in patients and suggests a strong potential for the application of gene editing as a therapeutic strategy.

Indexed as

Codon, NonsenseCRISPR-Cas SystemsFibroblastsGene EditingRetinoblastoma Binding ProteinsCell LineCell ProliferationHumansRetinoblastomaUbiquitin-Protein LigasesCodon, NonsenseRB1 protein, humanRetinoblastoma Binding ProteinsUbiquitin-Protein LigasesBase editingCRISPRNonsense mutationRB1Retinoblastoma

Identifiers

PMID40646080
PMCPMC12254293

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.